Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07851259) titled 'A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Genentech, Inc.
Condition:
Geographic Atrophy Secondary to Age-Related Macular Degeneration
Intervention:
Drug: RO7965032
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 30, 2026
Target Sample Size: 321
To know more, visi...